Exhibit 99.2

Unlocking Life Changing Therapies May 2026 C O R P O R A T E O V E R V I E W

©2026 R elm ada - Al l ri ghts r eserved Disclosures 2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "if", "may", "expects", "anticipates", "believes", "will", "will likely result", "will continue", "plans to", "potential", "promising", and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential for Phase 2 NDV-01 data to continue to deliver positive results supporting further development, potential for clinical trials to deliver statistically and/or clinically significant evidence of efficacy and/or safety, failure of interim or top-line results to accurately reflect the complete results of the trial, failure of planned or ongoing preclinical and clinical studies to demonstrate expected results, potential failure to secure FDA agreement on the regulatory path for sepranolone, and NDV- 01, or that future sepranolone, or NDV-01 clinical results will be acceptable to the FDA, failure to secure adequate sepranolone, or NDV-01 drug supply, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

©2026 R elm ada - Al l ri ghts r eserved Investment Thesis 3 Innovative pipeline of potential high-value assets, led by NDV-01 for non- muscle invasive bladder cancer (NMIBC) NDV-01, a late-stage sustained-release Gem/Doce with attractive commercial profile and well-defined regulatory pathway Improvement vs. conventional Gem/Doce, positioning NDV-01 as a next- generation standard-of-care driven by ease and speed of administration, extended tumor exposure and physician familiarity Proven efficacy of conventional Gem/Doce supported by positive clinical response and tolerability profile for NDV-01 reduce mechanistic and regulatory risk Experienced leadership team supported by leading urology KOLs with direct NMIBC trial and practice experience

©2026 R elm ada - Al l ri ghts r eserved Innovative Pipeline of Potential High-Value Assets 4 Candidate / Indication Phase 1 Phase 2 Phase 3 Status / Potential Next Steps NDV-011 High-Risk NMIBC (Study TRCG-001) 2026: Present data at upcoming medical meetings, continue enrollment NDV-01 Intermediate-Risk NMIBC (RESCUE Cohort 1) Mid-2026: Initiate RESCUE Phase 3 registrational Cohort 1 NDV-01 2L BCG-Unresponsive (RESCUE Cohort 2A)2 Mid-2026: Initiate RESCUE Phase 3 registrational Cohort 2A NDV-01 2L BCG-Unresponsive (RESCUE Cohort 2B)3 Mid-2026: Initiate RESCUE Phase 2 exploratory Cohort 2B Sepranolone Prader-Willi Syndrome (PWS) Mid-2026: Initiate Phase 2 study 2026/27: Identify next Indication 1. NDV-01: A sustained-release intravesical formulation of gemcitabine/docetaxel (Gem/Doce); 2. BCG-Unresponsive patients with CIS +/- Ta/T1 disease; Phase 3 Cohort 2A is a registrational cohort intended for regulatory approval. 3. BCG-Unresponsive patients with high-grade Ta/T1 disease. Cohort 2B is an exploratory cohort and not intended for regulatory appr oval. NMIBC: Non-muscle invasive bladder cancer; BCG: Bacillus Calmette-Guérin; 2L: Second Line Focused on programs with positive proof-of-concept data MID-2026 MID-2026 MID-2026 MID-2026

©2026 R elm ada - Al l ri ghts r eserved 5 NDV-01 A sustained-release intravesical formulation of gemcitabine/docetaxel (Gem/Doce) for patients with NMIBC, with positive Phase 2a data1 1. Relmada press release March 9, 2025 NMIBC: Non-muscle invasive bladder cancer. The graphic is for artistic purposes only, not a factual representation

©2026 R elm ada - Al l ri ghts r eserved Our Focus: Non-Muscle Invasive Bladder Cancer (NMIBC) 6 1. Shih K et al. Aging Dis. 2021. 2. Aldousari S et al. Can Urol Assoc J. 2013. 80% of new cases1,2 20% of new cases1,2 Muscle-invasive Non-muscle invasive NMIBC • Papillary tumors: non-invasive projections from the bladder surface • Carcinoma in situ (CIS): flat, aggressive cancer that is often unresectable MIBC • Tumors have invaded bladder muscle with or without lymph node involvement • Tumors may have spread to nearby organs but are not growing into the pelvic or abdominal wall

©2026 R elm ada - Al l ri ghts r eserved NMIBC Represents Multi-Billion Dollar Market Opportunity 7 1. National Cancer Institute (SEER). Cancer Stat Facts: Bladder Cancer. 2. American Cancer Society. Key Statistics for Bladder Cancer. 3. National Cancer Institute. Bladder Cancer Survival Data. 4. American Urological Association / SUO. NMIBC Guidelines (2024 Amendment). 5. Białek et al. EORTC Bladder Cancer Recurrence Calculator. 2024. 6. Seo et al. J Prev Med Public Health. 2018. 7. Nielsen et al. Cancer. 2013. 8. Shih K et al. Aging Dis. 2021. 9. Aldousari et al. Can Urol Assoc J. 2013. 10. Clark O et al. Pharmacoecon Open. 2024. NMIBC: Non-muscle invasive bladder cancer ~ 68,000 ~85,000 ~744,000 ~ 54,400 Key Highlights High incidence1 4.2% of all new cancer cases in the US High recurrence5 ~30%-61% of high-risk patients recur within one year. Multiple treatment courses High cost Complex treatment pathways $6.5B total annual cost (U.S.)10 Intermediate-risk and high-risk have increased risk of recurrence and progression (Intermediate-risk represents 45%6, 7 and high-risk represents 35%7 of NMIBC cases) New bladder cancer cases2 71-97% 5-year overall survival, 8% with advanced disease3 US prevalence of Bladder Cancer1 (Overall Bladder Cancer) NMIBC cancer cases (80% of bladder cancers)4,6,8,9 50-80% recurrence rate (over five years)5

©2026 R elm ada - Al l ri ghts r eserved Potential 2L NDV-01 Usage * NMIBC Patient Journey 8 Initial Testing Urologist performs cystoscopy and urine cytology. TURBT TURBT to stage, risk-stratify, and treat disease. Symptoms Patient presents to physician; most common presenting symptom is hematuria (blood in urine). Risked-Based Therapies Adjuvant therapy (chemotherapy, immunotherapy, systemic therapy) based on patients risk category. 4 Low-Risk Intermediate-Risk High-Risk BCG-Unresponsive 1 2 3 (*) Initial NDV-01 Registrational Pathways Based on AUA/SUO Practice Guidelines, 2024 (Event April 28, 2025 (Holzbeierlein et al. ("Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment"). NMIBC: Non-muscle invasive bladder cancer; BCG: Bacillus Calmette Guérin; TURBT: Trans Urethral Resection of Bladder Tumor; 2L: Second-line 5 Ongoing Surveillance Regular cystoscopy and urine cytology (up to every 3 months) to monitor for recurrence/progression. Perioperative Chemotherapy Perioperative Chemotherapy Perioperative Chemotherapy Intravesical BCG Intravesical Chemotherapy/BCG * Perioperative Chemotherapy Disease Recurrence Immunotherapy, Intravesical Chemotherapy, and Systemic Therapies

©2026 R elm ada - Al l ri ghts r eserved Systemic Therapy Overview of NMIBC Treatment Landscape 9 Intravesical Chemotherapy Gene Therapy/ Immunotherapy TURBT Surgery Relmada internal market research, 2025. 1. Pycha A et al. Urology. 2003. 2. Białek, Ł. (2024, August 1). EORTC Bladder Cancer Recurrence and Progression Calculator. Omni Calculator. NMIBC: Non-muscle invasive bladder cancer; TURBT: Transurethral resection of bladder tumor; BCG: Bacillus Calmette-Guérin Approved and emerging treatments Complications (>15%)1 OR procedure under anesthesia Patient burden Emerging dataset Conventional Chemotherapies: mitomycin, gemcitabine, Gem/Doce Sustained-Release: NDV-01 (Gem/Doce), INLEXZO (gemcitabine), ZUSDURI (mitomycin) Risk of recurrence (50-80%)2 Supply issues Complex handling requirements BCG, Adstiladrin®, Anktiva®, Cretostimogene, TARA-002, EG- 70, TAR-210 (FGFR inhibitor) Risk of recurrence Risk of immune-mediated or systemic side effects KEYTRUDA® (anti-PD1), Sasanlimab (anti-PD1), TYRA-300 (oral FGFR3)

©2026 R elm ada - Al l ri ghts r eserved The Burden of Recurrences and TURBT is High 10 • Complication rate > 15%2 • Grade 3/4 complication rate = 9.4%3 • Readmission rate = 5%4 • Procedural Cost = $7,000-$10,0005, 7 • Worsening mental health, physical health and lower urinary tract symptom scores6 1. Sharma V et al. Urology. 2023. 2 . Pycha A et al. Urology. 2003. 3. Bansal A et al. Indian J Urol. 2016. 4. Jindal T et al. Curr Urol. 2023. 5. MediGence TURBT cost data. 6. Lee LJ et al. Clinicoecon Outcomes Res. 2020. 7. Kokkotos F et al. J Clin Oncol. 2022 • 5-year risk of initial recurrence: 54.4%. After initial recurrence 60.1% of patients had a second recurrence by 2 years • After 2nd recurrence, 51.5% of patients had a 3rd recurrence by 3 years Frequent recurrences for IR NMIBC patients: ~ 1 recurrence / year1 Increased risk of progression with more recurrences1 Recurrences typically require TURBT Invasive OR procedure with anesthesia • The 5-year risk of progression: 9.5%, 21.9%, and 37.9% for patients with 1, 2, and 3+ recurrences, respectively

©2026 R elm ada - Al l ri ghts r eserved Gem/Doce Combination Stands Out in Urology Times Survey1 11 What is your preferred treatment for patients with BCG-unresponsive NMIBC? When selecting intravesical therapy after BCG- unresponsive NMIBC, which agent do you most commonly use? 1. Derived from Urology Times: Survey on Treatment Patterns and Preferences in Non–Muscle Invasive Bladder Cancer, June 2025, based on responses from 42 practicing physicians (Saylor, Benjamin P. "Survey: New NMIBC Treatments Face Slow Uptake." Urology Times, 17 July 2025. Clinical trial Nogapendekin alfa inbakicept (ANKTIVA®) Pembrolizumab (KEYTRUDA®) Intravesical chemotherapy Mitomycin-C Nogapendekin alfa inbakicept (ANKTIVA®) Nadofaragene Firadenovec (ADSTILADRIN®) Gemcitabine plus docetaxel (Gem/Doce) Gemcitabine Nadofaragene firadenovec (ADSTILADRIN®) 0% 20% 40% 60% 80% 100% 0% 20% 40% 60% 80% 100%

©2026 R elm ada - Al l ri ghts r eserved vs. <5 minutes for NDV-01 Significant Issues with Conventional Gem/Doce Intravesical Therapy for NMIBC 12 NMIBC: Non-muscle invasive bladder cancer; Gem/Doce: Gemcitabine plus Docetaxel 4-hour total procedure time First administration Preparation by specialized pharmacy ~60-120 min dwell time Second administration ~90-120 min dwell time 30 min break vs. NDV-01 comes ready for use in two pre-filled plastic syringes Requires specialized pharmacy preparation vs. NDV-01 which provides the opportunity for community urologist to deliver Gem/Doce Utilization concentrated in academic setting vs. NDV-01 which provides sustained release of Gem/Doce for up to 10 days Limited drug exposure and dwell time

©2026 R elm ada - Al l ri ghts r eserved NDV-01 - Targeted Sustained-Release Intravesical Gem/Doce 13 Diffusion through pores Diffusion through the polymer Osmotic pumping Erosion Bladder-targeted solid matrix enables prolonged tumor exposure to the cytotoxic drug combination via multiple delivery modalities

©2026 R elm ada - Al l ri ghts r eserved NDV-01 in-vitro Drug Concentrations Show Continuous & Optimized Drug Release 14 • In-vitro profiles demonstrate stable and predictable drug levels, minimizing peaks and troughs associated with systemic side effects. • Controlled drug exposure can potentially enhance anti-tumor activity while reducing the frequency of administration, enabling biweekly dosing. 0 10 20 30 40 50 60 70 80 90 100 0 20 40 60 80 100 120 140 160 180 200 Release, % Time (hours) Gemcitabine Release % Docetaxel Release % 0 5 10 15 20 25 30 0 500 1000 1500 2000 2500 3000 0 20 40 60 80 100 120 140 160 180 200 Docetaxel Gemcitabine Time (hours) Gem, µg/ml DCTX, µg/ml NDV-01 Gem/Doce Concentration Over Time NDV-01 Cumulative Release Profile Experimental overview: 12g NDV-01 with 10% gemcitabine, 0.25% docetaxel formulation was instilled into 10ml artificial urine (AU F) and kept in an orbital shaker incubator at 370C, 20 rpm. The AUF sample was withdrawn twice a day and replaced by fresh AUF. The drugs concertation in the UAF was quantitatively determin ed by HPLC

©2026 R elm ada - Al l ri ghts r eserved NDV-01: Clinically De-Risked with Clear Competitive Advantages 15 Ready for Use: Rapid, Office-Based Administration NDV-01 comes as two prefilled syringes instilled in < 5 minutes Convenience: Unlocks Community-Based Treatment In-office administration by MA/RN/LPN without specialized infusion infrastructure, supporting broad adoption in community urology practices where ~80% of NMIBC patients are treated Derisked Based on Conventional Gem/Doce Usage Conventional Gem/Doce is a well-understood and most commonly used in academic practice, providing familiarity and supporting a lower-risk clinical and regulatory pathway Prolonged Intravesical Tumor Exposure NDV-01 delivers continuous intravesical Gem/Doce inside the bladder enabling sustained tumor exposure Favorable Safety & Clearance Profile The NDV-01 biodegradable polymer gradually disintegrates and is safely excreted in urine, vs. Inlexzo which requires device extraction Relmada internal market research 2025. NMIBC: Non-muscle invasive bladder cancer; Gem/Doce: Gemcitabine plus Docetaxel; MA: Medical assistant; RN: Registered Nurse; LPN: Licensed practical

©2026 R elm ada - Al l ri ghts r eserved 16 Study TRCG-011 for High-Risk NMIBC An open-label, single-arm, single-center Phase 2a study to evaluate safety and efficacy of NDV-01 in HR NMIBC patients (NCT06663137) HR: High Risk; NMIBC: Non-muscle invasive bladder cancer

©2026 R elm ada - Al l ri ghts r eserved Inclusion Criteria Purpose Primary Endpoint Secondary Endpoint Exploratory Study Design 17 ONGOING TRCG-011 STUDY • High-risk disease with CIS, Ta/T 1 tumors1, 2 • BCG-naive, BCG- unresponsive, intolerant and experienced patients Evaluate the potential of NDV-01 as a safe and effective treatment for patients with high-risk NMIBC • Safety • CR Rate at 12 months • DOR • EFS • PK 1. The American Cancer Society. Bladder Cancer Stages. American Cancer Society, 12, Mar, 2024; 2. Holzbeierlein, Jeffrey M., et al. "Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment." The Journal of Urology, vol. 211, no. 4, Jan. 2024. CIS: Carcinoma In Situ; Ta: Noninvasive papillary carcinoma; T1: Tumor invades lamina propria; NMIBC: Non- muscle invasive bladder cancer; CR: Complete Response; DOR: Duration of Response; EFS: Event Free Survival; PK: Pharmacokinetics; TURBT: Transurethral resection of bladder tumor BCG: Bacillus Calmette-Guérin Follow up to 24 months Urinary cytology Cystoscopy Upper tract imaging TURBT or bladder biopsy if necessary N=70 High-risk NMIBC Intravesical NDV-01 Induction 6 biweekly instillations Maintenance Monthly instillations

©2026 R elm ada - Al l ri ghts r eserved Demographic Data 18 ONGOING TRCG-011 STUDY Characteristics N=48 % Age Median (range) 75 (52-93) yr Sex Male 42 87.5% Female 6 12.5% BCG doses Median BCG doses (range) 9 (3-23) BCG-status BCG-naive 23 47.9% BCG-exposed 5 10.4% BCG-unresponsive 20 41.7% Stage CIS +/- Ta/T1 12 25.0% Ta HG 29 60.4% T1 HG 7 14.6% BCG: Bacillus Calmette-Guérin; CIS: Carcinoma In Situ; Ta: Noninv asive papillary carcinoma; T1: Tumor invades lamina propria; HG: High grade

©2026 R elm ada - Al l ri ghts r eserved 01-002 CIS BCG-UR 01-007 T1 BCG-exposed 01-009 T1 BCG-UR 01-010 T1 BCG-naive 01-011 T1+CIS BCG-naive 01-013 Ta BCG-exposed 01-014 Ta BCG-naive 01-015 Ta BCG-naive 01-020 Ta BCG-UR 01-022 Ta BCG-naive 01-023 Ta BCG-naive 01-024 Ta BCG-naive 01-025 Ta BCG-naive 01-027 Ta BCG-UR 01-028 Ta BCG-UR 01-004 CIS BCG-naive 01-021 Ta BCG-UR 01-026 Ta BCG-UR 01-005 T1+CIS BCG-UR 01-003 CIS BCG-naive 01-030 Ta BCG-UR Pending 01-019 Ta BCG-UR Discontinued 01-032 Ta BCG-UR Pending 01-034 T1+CIS BCG-UR Pending 01-035 Ta BCG-UR Pending 01-018 Ta BCG-exposed Discontinued 01-029 Ta BCG-UR Discontinued 01-033 T1 BCG-naive Discontinued 01-036 Ta BCG-UR Pending 01-037 Ta BCG-exposed Pending 01-038 Ta BCG-naive Pending 01-039 Ta BCG-naive Pending 01-042 Ta+CIS BCG-naive Pending 01-043 Ta+CIS BCG-UR Pending 01-045 T1 BCG-naive Pending 01-046 Ta BCG-UR Pending 01-044 Ta BCG-naive Pending 01-001 T1 BCG-naive Discontinued 01-047 Ta BCG-naive Pending 01-049 Ta BCG-naive Pending 01-050 Ta BCG-naive Pending 01-051 Ta BCG-exposed Pending 01-052 Ta BCG-naive Pending 01-054 CIS BCG-UR Pending 01-055 CIS BCG-UR Pending 01-059 CIS BCG-UR Pending 01-060 T1 BCG-naive Pending 01-062 CIS BCG-naive Pending 3 months 6 months 9 months Patient # 12 months NDV-01 Provided Durable Response Over Time 19 ONGOING TRCG-011 STUDY Stage BCG status Discontinued 95% Anytime CR rate 87% 3-month CR rate 86% 6-month CR rate 85% 9-month CR rate CR: Complete response; BCG: Bacillus Calmette-Guérin; BCG-UR: BCG-unresponsive; KM: Kaplan-Meier analysis 76% 12-month CR rate CR Non-CR Re-induced Ongoing

©2026 R elm ada - Al l ri ghts r eserved Efficacy Results 20 ONGOING TRCG-011 STUDY n/N % Anytime 36/38 95% 3-month 33/38 87% 6-month 25/29 86% 9-month 22/26 85%* 12-month 19/25 76%* 12-month KM analysis - 83% • No patient had progression to muscle invasive disease • No patient underwent a radical cystectomy • 10 patients awaiting 3-month response assessment – Including 3 BCG-unresponsive CIS patients 1. Efficacy evaluable patients (n=38) includes patients with at least 3-month follow-up assessment. *Includes patients with CR after re-induction. 80% CR rate after re-induction; 2. https://www.fda.gov/media/101468/download; BCG: Bacillus Calmette-Guérin; BCG-UR: BCG-unresponsive; KM: Kaplan-Meier analysis n/N % Anytime 16/17 94% 3-month 14/17 82% 6-month 12/14 86% 9-month 10/11 91% 12-month 8/10 80% 12-month KM analysis - 84% • n = 20 patients dosed in BCG-UR subpopulation • BCG-UR defined by FDA definition2 BCG-UR Subpopulation (Complete Response) Efficacy Evaluable Patients1 (Complete Response)

©2026 R elm ada - Al l ri ghts r eserved Treatment-Related AE and Tolerability 21 ONGOING TRCG-011 STUDY No patient had ≥ Grade 3 TRAE No patients discontinued treatment due to AEs Of the 48 patients who received ≥ 1 dose of NDV-01, 30 (63%) had a TRAE • 54% transient uncomfortable urination (dysuria) • 8% asymptomatic positive urine culture • 8% hematuria TRAE: Treatment-related adverse events; AE: Adverse events

©2026 R elm ada - Al l ri ghts r eserved BCG-Unresponsive NMIBC: The Presence of CIS Does NOT Impact Gem/Doce RFS1 22 1. As demonstrated by third-party data: Steinberg et al. J Urol. 2020;203:902–909; BCG: Bacillus Calmette-Guérin; CIS: carcinoma in situ; RFS: recurrence-free survival; HG: High grade Steinberg et al. (2020): n=276; heavily-pre-treated with BCG 12-month RFS: • Any CIS = 60% • HG papillary alone = 61% Cox regression analysis for risk factors: • Presence of CIS does NOT Impact RFS (p=0.15)

©2026 R elm ada - Al l ri ghts r eserved Two Independent NDV-01 Approval Pathways Provide Significant Market Opportunity 24 PHASE 3 RESCUE TRIAL 1. Based on Internal estimates. 2. Grabe-Heyne et al. Front Oncol. 2023. 3. FDA approval summaries; company disclosures; published clinical trial data. NMIBC: Non-muscle invasive bladder cancer; BCG: Bacillus Calmette-Guérin (BCG); TURBT: Transurethral Resection of Bladder Tumor; CIS: carcinoma in situ; 1L: first-line; 2L: second-line; CR: Complete Response; ~75k patients/annually in US1 – with ~35%2 of intermediate-risk patients receiving adjuvant therapy post-TURBT Registrational Pathway 2 Open label randomized controlled trial in intermediate-risk NMIBC – adjuvant therapy following TURBT (NDV-01 vs. observation) ~5k patients/annually in US1 – based on 12-month CR rates of 19%-46%3 for 1L BCG-unresponsive therapies Registrational Pathway 1 Single-arm trial in 2L BCG-unresponsive NMIBC with CIS who are refractory to approved or developmental 1L therapies

©2026 R elm ada - Al l ri ghts r eserved Cohort 2A: 2L BCG-Unresponsive NMIBC 25 PHASE 3 RESCUE TRIAL Open-label, single-arm study to evaluate safety and efficacy of NDV-01 in BCG-UR refractory to first-line therapy Study design Inclusion Criteria Purpose • HR BCG-UR with CIS refractory to first-line therapy • Safety and efficacy of NDV-01 in patients with HR BCG-UR with CIS Secondary Endpoint Primary Endpoint Other • CR anytime • Safety • DOR • PFS • RFS amongst responders • PK 1. BCG-Unresponsive patients with CIS +/- Ta/T1 disease. Phase 3 Cohort 2A is a registrational cohort intended for regulatory appro val. 2. BCG-Unresponsive patients with high-grade Ta/T1 disease. Phase 2 Cohort 2B is an exploratory cohort and not intended for regulatory approval. HR: High risk; CIS: Carcinoma In Situ; CR: Complete Response; DOR: Duration of Response; RFS: Recurrence Free Survival; PFS: Progression Free Survival; PK: Pharmacokinetics; TURBT: Transurethral resection of bladder tumor; BCG: Bacillus Calmette-Guérin BCG-UR: BCG-unresponsive Intravesical NDV-01 Induction 6 biweekly instillations Maintenance Monthly instillations Follow up to 24 months Urinary cytology Cystoscopy TURBT or bladder biopsy if necessary Cohort 2A1 (Registrational; N=87) HR BCG-UR NMIBC with CIS refractory to 1st line therapy

©2026 R elm ada - Al l ri ghts r eserved Cohort 1: Adjuvant Intermediate-Risk NMIBC 26 PHASE 3 RESCUE TRIAL Registrational Randomized study of TURBT + NDV-01 vs. TURBT in IR NMIBC Inclusion Criteria Primary Endpoint • IR NMIBC • IBCG risk factors ≥ 1 • DFS* • Safety Intravesical NDV-01 Induction 6 biweekly instillations + maintenance Observation Option to have Induction with NDV-01 with recurrence Follow up to 24 months Urinary cytology Cystoscopy Upper tract imaging TURBT or bladder biopsy if necessary DFS: Disease Free Survival; IR: Immediate Risk; HG-RFS: High Grade Recurrence Free Survival; PFS: Progression Free Survival; QOL: Quality of Life Metrics; TURBT: Transurethral resection of bladder tumor; IBCG: International Bladder Cancer Group; LG: Low grade; HG: High grade Cohort 1 (Registrational; N=276) TURBT within 12 weeks (+/- single-dose peri-operative chemotherapy) Study design *DFS = time from randomization to the date of the first documented recurrence/progression. Stratification Factors: • LG vs. HG • Single-dose peri-operative chemotherapy: yes vs. no Secondary Endpoint • HG-RFS • PFS • QOL

©2026 R elm ada - Al l ri ghts r eserved Expecting to Advance NDV-01 Towards Registration-Track Studies in Mid-2026 27 Interim Phase 3 2L BCG-Unresponsive 3-month Data Initial 3-month CR data + safety Mid 2026 YE 2026 BCG: Bacillus Calmette-Guérin (BCG); NMIBC: No muscle invasive bladder cancer; IR: Intermediate Risk Initiate Phase 3 RESCUE Trial Target two independent registrational pathways: • 2L BCG-Unresponsive NMIBC patients • Adjuvant Intermediate-Risk NMIBC patients

©2026 R elm ada - Al l ri ghts r eserved Sepranolone Has the Potential to Normalize GABAA Receptor Activity 29 GABA (Υ-aminobutyric acid) is the primary neurotransmitter, involved in anxiety and compulsive disorders1,2 Allopregnanolone (ALLO) typically enhances GABAA calming effects3, 4 In some individuals, ALLO exacerbates anxiety and compulsivity5, 6 Sepranolone normalizes GABAA receptor activity without interfering in GABA signaling7,8 1. Nuss P et al. Neuropsychiatr Dis Treat. 2015. 2. Möhler H. Neuropharmacology. 2012. 3. Belelli D et al. Nat Rev Neurosci. 2005. 4. Majewska MD et al. Science. 1986. 5. Girdler SS et al. Biol Psychiatry. 2001. 6. Bixo M et al. Br J Psychiatry. 2025. 7. Bixo M et al. Psychoneuroendocrinology. 2017. 8. Bäckström T et al. Psychoneuroendocrinology. 2021. GABAA: Υ-aminobutyric acid type A; ALLO: Allopregnanolone

©2026 R elm ada - Al l ri ghts r eserved OCD is characterized by intrusive, unwanted thoughts (obsessions) and repetitive behaviors (compulsions) US prevalence 8.2M people4 Neurological disorder characterized by repetitive, involuntary tics, with childhood onset US prevalence 350-450K children and adults3 Neurological disorder that causes involuntary, rhythmic shaking. Primarily notice during voluntary movements US prevalence 6.4 MM people2 Genetic disorder often defined by persistent hunger and overeating Global prevalence 350-400K people1 Positive Phase 2 Data and Unique MOA Give Sepranolone Broad Potential 30 Prader-Willi Syndrome Essential Tremors Tourette Syndrome Obsessive- Compulsive Disorder and related disorders 1. Scheimann AO. UpToDate. 2023. 2. Crawford S et al. Neurology. 2020. 3. Tinker SC et al. Psychiatry Res. 2022. 4. International OCD Foundation epidemiology data. PWS: Prader-Willi syndrome; ET: Essential Tremor; OCD: Obsessive Compulsive Disorder

©2026 R elm ada - Al l ri ghts r eserved Sepranolone: Highlights & Development Value 31 Differentiated therapeutic candidate for compulsivity-related disorders, supported by positive proof-of-concept data in Tourette's syndrome Phase 2 study in Prader-Willi syndrome (PWS) planned for mid-2026, targeting a rare genetic disorder affecting 350,000–400,000 individuals worldwide Program readiness: Regulatory engagement and manufacturing activities are actively underway, supporting efficient trial initiation Orphan/rare disease incentives: Potential for orphan drug designation, including regulatory exclusivity, accelerated approval pathways, and enhanced commercial visibility Strategic investor value: Clear development milestones, potential for first- in-class differentiation, and meaningful opportunity in a high-unmet-need rare disease

©2026 R elm ada - Al l ri ghts r eserved Expecting to Advance Sepranolone Towards Phase 2 Study in Prader-Willi Syndrome in Mid-2026 32 Initiation of Pilot Phase 2 study in Prader-Willi Syndrome Focus on evaluating early proof-of-concept PWS: Prader-Willi syndrome Mid 2026

©2026 R elm ada - Al l ri ghts r eserved Financial Overview 34 Gross proceeds from PIPE (net ~$150M million) Provides cash runway through 2029 Cash, cash equivalents & short-term investments As of March 31, 2025 Common shares outstanding ~127.9 million as converted – includes ~15.0M outstanding options (weighted average exercise price of $12.51/share) and ~8.0M outstanding warrants $234.0 million1 $160 million PIPE2 ~104.9 million3 1. As of March 31, 2026 – Includes net proceeds of ~$150M from PIPE on March 9, 2026 ; 2. On March 9, 2026; 3. As of March 31, 2026

Thank You!

Appendix

©2026 R elm ada - Al l ri ghts r eserved Gem/Doce combination has been embraced by the urologic oncology community 37 Effective salvage treatment for patients who have failed or are intolerant to BCG with reported 2-year RFS ~50%1, 2, 3 Gem/Doce is an effective alternative first-line agent in high-risk BCG naïve patients with 2-year RFS of 82%4 Gem/Doce use expanding into intermediate-risk and low-grade tumors with reported 2-year RFS of 70-80%5, 6 Gem/Doce avoids/delays radical cystectomy7, 8 Large ongoing cooperative "BRIDGE" study (n=870) evaluating Gem/Doce combination vs. BCG (NCT05538663) 1. Steinberg RL et al. J Urol. 2020; 2. Garneau CA et al. Can Urol Assoc J. 2024; 3. Yim K et al. Urol Oncol. 2023; 4. McElree IM et al. J Urol. 2022; 5. McElree IM et al. Urol Oncol. 2023; 6. Tan WS et al. Eur Urol Oncol. 2023; 7. Chevuru PT et al. Urol Oncol. 2023; 8. Narayan VM et al. J Urol. 2024. 9. Steinberg RL et al. J Urol. 2019; RFS: Relapse Free Survival; BCG: Bacillus Calmette-Guérin; NMIBC: Non-muscle invasive bladder cancer; Gem/Doce: Gemcitabine plus Docetaxel

©2026 R elm ada - Al l ri ghts r eserved Cohort 2B: 2L BCG-Unresponsive NMIBC 38 Open-label, single-arm study to evaluate safety and efficacy of NDV-01 in BCG-UR refractory to first-line therapy Study design PHASE 3 RESCUE TRIAL Inclusion Criteria Purpose • HR BCG-UR papillary only refractory to first-line therapy • Safety and efficacy of NDV-01 in patients with HR BCG-UR with CIS Secondary Endpoint Primary Endpoint Other • CR anytime • Safety • DOR • PFS • RFS amongst responders • PK 1. BCG-Unresponsive patients with high-grade Ta/T1 disease. Phase 2 Cohort 2B is an exploratory cohort and not intended for regulatory approval. CR: Complete Response; DOR: Duration of Response; RFS: Recurrence Free Survival; PFS: Progression Free Survival; BCG-UR: BCG-unresponsive Intravesical NDV-01 Induction 6 biweekly instillations Maintenance Monthly instillations Follow up to 24 months Urinary cytology Cystoscopy TURBT or bladder biopsy if necessary Cohort 2B1 (Exploratory; N=30) HR BCG-UR NMIBC papillary only refractory to 1st line therapy

©2026 R elm ada - Al l ri ghts r eserved Management 40 Leadership Sergio Traversa Chief Executive Officer Maged Shenouda Chief Financial Officer Chuck Ence Chief Accounting and Compliance Officer Paul Kelly Chief Operating Officer Raj S. Pruthi, MD Chief Medical Officer Charles J. Casamento Chairman of the Board John Glasspool Director Fabiana Fedeli Director Sergio Traversa Chief Executive Officer Board of Directors Paul Kelly Chief Operating Officer